+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 50Years +
All Genders
ID07844148

Comparing the Effectiveness and Safety of GNR-139 and Eylea in Adults with Neovascular Age-Related Macular Degeneration

Led by AO GENERIUM · Updated on 2026-09-30

180

Participants Needed

14

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the investigational drug GNR-139 compared to the reference drug Eylea in patients with neovascular age-related macular degeneration nAMD who have not received prior treatment. This multicenter, randomized, double-blind study aims to assess whether GNR-139 has similar effectiveness and safety as Eylea by measuring changes in visual acuity. Participants will be randomly assigned in a 21 ratio to receive either GNR-139 or Eylea, both administered as an 8 mg intravitreal injection. The study includes two groups 120 patients receiving GNR-139 and 60 patients receiving Eylea. Treatments are given by injection into the eye, and neither participants nor doctors know which drug is given. Throughout the study, participants will have their visual acuity measured using the ETDRS chart at multiple time points up to Week 56. Optical coherence tomography OCT and fluorescein angiography FFA will assess retinal changes and lesion areas. Researchers will monitor safety, immunogenicity, and treatment effects over one year, including tracking the number of injections and any adjustments needed in treatment intervals.

CONDITIONS

Brief Title

A Study to Compare GNR-139 and Eylea® in Patients With nAMD

Research Team

O

Oksana Markova, MD

A

Anton Seleznev, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here